K-877 compound: Clinical Trials

13 trials of K-877 compound, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 1 terminated. 9 Phase 1, 3 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 19Completed 9
Phase 33Completed 2, Terminated 1
Phase 21Completed 1

Follow K-877 compound: new trials by email Literature Review of K-877 compound trials Research Report on K-877 compound

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Assess the Food Effect of K-877 in Healthy Adult Volunteers
K-877 - Healthy
Phase 1CompletedKowa Research Institute, Inc.182021-01-132021-08-09
Pharmacokinetic Drug-Drug Interaction Study Between K-877 and CSG452 in Healthy Adult Volunteers
K-877, CSG452 - Healthy
Phase 1CompletedKowa Research Institute, Inc.202019-12-172020-09-22
A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
K-877, Placebo - Non-Alcoholic Fatty Liver Disease
Phase 2CompletedKowa Company, Ltd.1182017-12-272021-04-09
Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
K-877, Placebo - Type2 Diabetes, Dyslipidemia
Phase 3TerminatedKowa Research Institute, Inc.105442017-03-232025-09-25
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
K-877, Fenofibrate, Placebo (for K-877) - Severe Hypertriglyceridemia
Phase 3CompletedKowa Research Institute, Inc.5512016-11-282022-11-30
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment
K-877, Fenofibrate, Placebo (for K-877) - Severe Hypertriglyceridemia
Phase 3CompletedKowa Research Institute, Inc.4712016-11-262022-10-28
Drug-Drug Interaction Study to Assess the Effects of Multi Dose Clopidogrel on the Pharmacokinetics of Single-Dose K-877 in Healthy Adult Volunteers
K-877, Clopidogrel - Healthy
Phase 1CompletedKowa Research Institute, Inc.202016-09-012016-12-21
Drug-Drug Interaction Study to Assess the Effects of Multiple-Dose Administration of K-877 on the Pharmacodynamics and the Pharmacokinetics of Multiple-Dose Administration of Warfarin in Healthy Adult Volunteers
Warfarin, K-877 - Healthy
Phase 1CompletedKowa Research Institute, Inc.202016-01-012016-03-25
Drug-Drug Interaction Study in Healthy Adult Volunteers
K-877, Rifampin - Healthy
Phase 1CompletedKowa Research Institute, Inc.202014-09-012016-02-01
Drug-Drug Interaction Study in Health Adult Volunteers
Digoxin, K-877 - Healthy
Phase 1CompletedKowa Research Institute, Inc.202014-08-012014-10-24
Drug-Drug Interaction Study in Healthy Adult Volunteers
K-877, Fluconazole - Healthy
Phase 1CompletedKowa Research Institute, Inc.202014-07-012014-10-27
Drug-Drug Interaction Study in Healthy Adult Volunteers
K-877, Cyclosporine - Healthy
Phase 1CompletedKowa Research Institute, Inc.202014-06-012014-10-27
Drug-Drug Interaction Study in Healthy Adult Volunteers
K-877, Clarithromycin - Healthy
Phase 1CompletedKowa Research Institute, Inc.202014-06-012014-10-27

Conditions studied

Hypertriglyceridemia (2)  ·  Dyslipidemias (1)  ·  Non-alcoholic Fatty Liver Disease (1)

Sponsors

Kowa Research Institute, Inc. (12)  ·  Kowa Company, Ltd. (1)

Countries

United States (12)  ·  Bulgaria (3)  ·  Czechia (3)  ·  Hungary (3)  ·  Poland (3)  ·  Russia (3)  ·  Ukraine (3)  ·  Belarus (2)  ·  Georgia (2)  ·  Japan (2)  ·  Argentina (1)  ·  Brazil (1)  ·  Canada (1)  ·  Colombia (1)  ·  Denmark (1)

Top investigators

Stuart Campbell (5)  ·  Aruna Pradhan, MD (1)  ·  Paul Ridker, MD (1)  ·  Ryohei Tanigawa (1)  ·  Shona Pendse, MD, MMSc (1)

Results publications

PMID 30342298, PMID 33392801, PMID 34528723, PMID 36342113, PMID 41953251